Meet with BEC at the 10th Young Member’s Boron Neutron Capture Therapy (YBNCT) meeting in Helsinki Finland, September 26-29, 2019. The BEC exacure system is particularly suited to operate safely in the difficult Neutron environment and enables secure patient positioning for BNCT. Use the opportunity to visit the first Western accelerator based BNCT facility at Helsinki University Hospital in Finland, supplied by Neutron Therapeutics equipped with the BEC exacure system.


Exacure modules

Since more than a decade BEC cooperates closely with leading treatment centers and research institutes in radiotherapy. Based on this massive experience and knowledge we designed a system that complies with or even exceeds the requirements for future patient positioning. With exacure we offer a cutting-edge system that flexibly combines robotic patient positioning with additional modules for high-end radiotherapy.


Components with high radiation resistance for BNCT

The requirements for medical devices that are used for BNCT treatment differ substantially from the requirements for systems used in conventional radiotherapy, as material properties are degraded by the neutron irradiation. Depending on the spectrum of the neutrons the exposure limits the life time of components or makes them even unsuitable for BNCT treatment. The exacure system from BEC is currently the only certified medical device available that meets those challenging requirements and ensures patient safety during BNCT treatment with the full range of functions, including patient positioning and imaging.

Boron Neutron capture therapy (BNCT) is a unique non-invasive type of radiation therapy for treating tumors with a two-step procedure. First, the patient is injected with a tumor-seeking drug containing a non-radioactive isotope (boron-10) with a high neutron capture cross-section. In the second step, the patient is exposed to a beam of low energy neutrons. After losing energy as they penetrate tissue, the neutrons are captured by the boron, which subsequently emits high-energy alpha particles that can selectively kill those tumor cells that have taken up sufficient quantities of boron. Scientific studies demonstrate that these particles systematically destroy the tumor cells while imparting relatively little damage to adjacent areas of healthy tissue. BNCT can make the process of radiation treatment much less onerous for the patient and has the potential to greatly improve therapeutic outcomes by treating the primary tumor site as well as undetected metastases in local region of the tumor.

BEC exacure patient positioning for BNCT

About BEC

BEC is a German robotic specialist that develops high-tech applications for radiotherapy, located in Pfullingen / Germany. Since the company was founded in 2003, BEC has steadily evolved into a technology leader for high-precision robotic applications. Today we deliver our systems to medical device manufacturers, clinics and research institutes worldwide. At BEC innovation is not just a buzz word, it's our mission! Innovation continuously and sustainably improves our products and services across all business units. Our target is to supply our customers with high-quality products and to help increase efficiency and accuracy with the best technology available.

"Irradiating a tumor accurately while sparing the surrounding healthy tissue, calls for the ultimate solution in patient positioning technology. Transferring cutting-edge technology from industrial applications to medical robotics was a key factor to the successful development of the exacure system."
Matthias Buck, CEO